EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EyePoint Pharmaceuticals Inc
Other Equity
EyePoint Pharmaceuticals Inc
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Other Equity
$961k
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Equity
-$14.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Equity
-$1.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Equity
-$8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Equity
-$4.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Equity
-$2.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
5%
|
|
EyePoint Pharmaceuticals Inc
Glance View
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2005-01-27. The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its Durasert technology with vorolanib, a tyrosine kinase inhibitor (TKI), which has demonstrated anti-VEGF activity. The firm has two commercial products, YUTIQ and DEXYCU. YUTIQ is a non-erodible intravitreal implant containing fluocinolone acetonide (FA) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes its Durasert sustained-release drug delivery technology platform. DEXYCU is an indicated for the treatment of post-operative ocular inflammation. DEXYCU utilizes its Verisome drug-delivery technology. The firm is also advancing YUTIQ 50, a six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the causes of blindness under a supplemental new drug application (sNDA) strategy.
See Also
What is EyePoint Pharmaceuticals Inc's Other Equity?
Other Equity
961k
USD
Based on the financial report for Dec 31, 2025, EyePoint Pharmaceuticals Inc's Other Equity amounts to 961k USD.
What is EyePoint Pharmaceuticals Inc's Other Equity growth rate?
Other Equity CAGR 10Y
1%
Over the last year, the Other Equity growth was -7%. The average annual Other Equity growth rates for EyePoint Pharmaceuticals Inc have been 6% over the past three years , 4% over the past five years , and 1% over the past ten years .
